Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both Donthe sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins. In men, hair loss occurs in a well-defined pattern, beginning from above the temples and over a period, the hairline recedes to form a characteristic "M" shape. The pattern of hair loss in women differs from male-pattern baldness. The distinctive feature of androgenic alopecia is progressive and gradual miniaturization of hair follicles, accompanied by progressive decrease in the duration of anagen, and reduction of anagen to telogen ratio.
ANDROGENIC ALOPECIA DRUG CANDIDATES UNDER DEVELOPMENT (2017)
Many pharmaceutical companies are actively involved in drug discovery process using novel targets, for the treatment of androgenic alopecia. Aclaris Therapeutics, Inc. updated its pipeline by adding a Pre-Clinical drug candidate namely, topical Janus Kinase (JAK) inhibitors drug candidate, for the treatment of men suffering from androgenic alopecia. However, the pipeline contains proportion of products from established drug classes, with improved dosing regimens and administration routes compared with currently marketed products.
The androgenic alopecia therapeutics pipeline comprises approximately 24 drug candidates, in different stages of development.
Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.